Navidea announces interim analysis for Phase III Lymphoseek trial

01/6/2013 | Business Wire

Navidea Biopharmaceuticals said it has gathered a sufficient number of participants in its NEO3-06 Phase III trial to do a pre-planned interim analysis of Lymphoseek in patients with head and neck cancer. The analysis will compare the pathological findings on sentinel lymph nodes identified using Lymphoseek with those of lymph nodes removed in a full nodal dissection surgery of the head and neck. Findings from the analysis are expected later this year.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI